PepGen (PEPG) to Announce Earnings on Thursday

PepGen (NASDAQ:PEPG) is projected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect PepGen to announce earnings of ($0.30) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

PepGen (NASDAQ:PEPG) last announced its earnings results on Tuesday, May 12th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. On average, analysts expect PepGen to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PepGen Price Performance

PEPG opened at $1.88 on Tuesday. The company has a market capitalization of $130.04 million, a price-to-earnings ratio of -1.07 and a beta of 1.89. The business’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $3.19. PepGen has a 1 year low of $1.01 and a 1 year high of $7.80.

Analyst Ratings Changes

A number of brokerages recently issued reports on PEPG. Wall Street Zen raised PepGen from a “sell” rating to a “hold” rating in a research report on Sunday, June 7th. Weiss Ratings cut shares of PepGen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. HC Wainwright reiterated a “buy” rating on shares of PepGen in a report on Thursday, May 21st. Wedbush cut their price objective on shares of PepGen from $5.00 to $4.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 13th. Finally, Craig Hallum initiated coverage on shares of PepGen in a research report on Tuesday, June 16th. They issued a “buy” rating and a $11.00 target price for the company. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Investors Weigh In On PepGen

Large investors have recently modified their holdings of the business. Burkehill Global Management LP bought a new stake in PepGen during the 3rd quarter worth $46,000. Militia Capital Partners LP acquired a new stake in shares of PepGen in the third quarter valued at about $72,000. ADAR1 Capital Management LLC lifted its stake in shares of PepGen by 81.0% in the third quarter. ADAR1 Capital Management LLC now owns 36,842 shares of the company’s stock worth $170,000 after acquiring an additional 16,490 shares during the period. Rangeley Capital LLC boosted its stake in shares of PepGen by 133.3% in the 2nd quarter. Rangeley Capital LLC now owns 35,000 shares of the company’s stock valued at $39,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Trexquant Investment LP acquired a new position in PepGen in the fourth quarter valued at $158,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Company Profile

PepGen, Inc (NASDAQ: PEPG) is a clinical-stage biotechnology company headquartered in San Diego, California. The company is developing precision gene editing therapies to address rare genetic diseases by combining advanced prime editing modalities with proprietary delivery technologies. PepGen’s platform is designed to achieve targeted and durable correction of disease-causing mutations in vivo, with the goal of providing long-lasting therapeutic benefit after a single administration.

The company’s lead development programs include PPG-001 for mucopolysaccharidosis type II (Hunter syndrome) and PPG-002 for mucopolysaccharidosis type I (Hurler syndrome).